Drug Trial Radar · NCT05155254
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
407
Actual
Start
May 17, 2022
Primary completion
May 30, 2025
Study completion Sep 2027
Sponsor
- Lead sponsor
- IO BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; Merck Sharp & Dohme LLC
- First posted
- Dec 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma. Patients will be stratified on the basis of the following factors; Disease stage: Stage III (unresectable) and IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type. All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment). Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102 IO103 will thereafter be administered subcutaneous every 3 weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years of treatment). The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone) in terms of progression free survival.
Conditions
- Metastatic Melanoma
- Unresectable Melanoma
Interventions
IO102-IO103Drug
IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
PembrolizumabDrug
Pembrolizumab administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Approximately 3.5 years
Locations
112 sites in 16 countries. Site status is shown where the registry gives one.
Mid Florida Hematology and Oncology Center
Orange City, Florida
Orlando Health Cancer Institute
Orlando, Florida
Roswell Park Cancer Institute
Buffalo, New York
VCU Massey Cancer Center
Richmond, Virginia
Sunshine Coast University Hospital
Birtinya, Australia
Peter MacCallum Cancer Centre PMCC - East Melbourne
Melbourne, Australia
Border Medical Oncology Research Unit
Albury, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Cairns Hospital
Cairns, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
AZ Nikolaas
Sint-Niklaas, Belgium
Universitair Ziekenhuis Gent UZ Gent
Ghent, Oost-Vlaanderen, Belgium
FNHK Klinika onkologie a radioterapie
Hradec Králové, Czechia
Fakultni Nemocnice Olomouc
Olomouc, Czechia
FN Ostrava
Ostrava, Czechia
FNKV Department of Dermatology
Prague, Czechia
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Herlev og Gentofte Hospital
Herlev, Denmark
Odense University Hospital
Odense, Denmark
Centre Hospitalier Universitaire de Besançon Jean Minjoz
Besançon, France
Centre Hospitalier Universitaire de Bordeaux Hospital Saint Andre
Bordeaux, France
Hopital Ambroise
Boulogne-Billancourt, France
Centre Georges Francois Leclerc
Dijon, France
Chu Grenoble - Hopital Albert Michallon
La Tronche, France
Centre Hospitalier Universitaire de Lille
Lille, France
Hôpital de La Timone
Marseille, France
CHU de Nice Hpital de lArchet 2
Nice, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Eugene Marquis
Rennes, France
Institut de Cancérologie de L'Ouest
Saint-Herblain, France
Centre Hospitalier de Valence (CHV)
Valence, France
Gustave Roussy
Villejuif, France
Universitatsklinikum Augsburg Medizincampus Sued
Augsburg, Germany
Charite Universitaetsmedizin Berlin
Berlin, Germany
St. Josef Hospital - Ruhr-Universitt Bochum
Bochum, Germany
University Hospital Erlangen
Erlangen, Germany
Universitaetsklinikum Essen
Essen, Germany
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.